Saturday 17 October 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMP Healthcare Biotechnology
CAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024. In the quarter to June 2026, revenue grew 18.8%, EPS grew 6.45% and free cash flow fell 23.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.17
0.28
−8.12%
Follow CAMP
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 4.06 | 1.31 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 12.30 | 7.31 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 58 | 55 | 48 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.01 | 0.01 | 0.07 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 1 | 3 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | — | — | (44) | (49) | (52) | (80) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | (14,083.14) | (7,943.40) | (2,298.54) | |||||
| Net income | — | — | — | — | — | — | (44) | (49) | (52) | (80) | |||||
| Depreciation | — | — | — | — | — | — | 1 | 2 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.89 | 0.14 | 0.12 | ||||
| Earnings | — | — | — | — | — | — | (141.51) | (124.79) | (11.04) | (2.65) | |||||
| Cash flow | — | — | — | — | — | — | (123.42) | (111.78) | (9.71) | (0.97) | |||||
| Capex | — | — | — | — | — | — | (12.89) | (1.72) | (0.09) | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | (136.30) | (113.50) | (9.81) | (0.98) | |||||
| Book value | — | — | — | — | — | — | 270.94 | 97.26 | 13.46 | 1.57 | |||||
| Shares, m | — | — | — | — | — | — | 0 | 0 | 5 | 30 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 53.24 | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.39 | 3.90 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 21.56 | |||||
| EV/FCF | — | — | — | — | — | — | — | (0.08) | 0.86 | (2.53) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (39) | (44) | (46) | (30) | ||||
| Capex | — | — | — | — | — | — | (4) | (1) | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (43) | (45) | (46) | (30) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 76 | 32 | 57 | 99 | ||||
| Total debt | — | — | — | — | — | — | 0 | 0 | 0 | — | |||||
| Net debt | — | — | — | — | — | — | (83) | (38) | (64) | (111) | |||||
| Shareholders’ equity | — | — | — | — | — | — | 85 | 38 | 63 | 48 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (62.59) | (77.73) | (82.00) | ||||
| ROIC | — | — | — | — | — | — | (1,790.30) | (17,526.69) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | 48.98 | 170.97 | (145.07) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
CAMP4 Therapeutics Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics, Inc. | $220.1M | — (loss-making) | — (loss-making) | −99.83% (below 0%: shrinking) | n/m | +32.19% (above 0%: growing) | 100.00% | 0.00% | Compare |
| PLX Protalix BioTherapeutics, Inc. | $217.5M | 10.9× | 10.2× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| CAMP CAMP4 Therapeutics Corporation | $216.5M | — (loss-making) | — (loss-making) | +18.84% (above 0%: growing) | n/m | −23.90% (below 0%: shrinking) | 100.00% | (752.11%) | |
| PYXS Pyxis Oncology, Inc. | $215.3M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| EVMN Evommune Inc. | $215.2M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MGNX MacroGenics, Inc. | $214.7M | — (loss-making) | — (loss-making) | +377.97% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| ALEC Alector, Inc. | $213.3M | — (loss-making) | — (loss-making) | −57.84% (below 0%: shrinking) | n/m | +30.19% (above 0%: growing) | 100.00% | (734.73%) | Compare |
| IFRX InflaRx N.V. | $212.2M | — (loss-making) | — (loss-making) | −128.93% (below 0%: shrinking) | n/m | +69.33% (above 0%: growing) | 14,029.95% | 0.00% | Compare |
| ZNTL Zentalis Pharmaceuticals, Inc. | $212.1M | — (loss-making) | — (loss-making) | — | n/m | −9.06% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $214.9M | — | — | −57.84% | — | +17.33% | 100.00% | 0.00% |
CAMP4 Therapeutics Corporation (CAMP) key facts
- Strength: CAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024.
- CAMP4 Therapeutics Corporation (CAMP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CAMP traded at $3.17, a market capitalization of $216.5 million.
- Return on equity was −145.1% and debt-to-equity 0.00.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −2.32 (distress zone) for fiscal 2025.